Language: BG BG
← Back to results
Active (not recruiting) Not applicable NCT05455021

Feasibility Study of the Vessel Restoration System (VRS) for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery (SFA) and/or Popliteal Artery (PA) After Sub-optimal Percutaneous Transluminal Angioplasty (PTA) or Atherectomy: REACTIVATE I

No applicable phase (e.g. observational)
Conditions: PAD - Peripheral Arterial Disease

Sponsor: Alucent Biomedical

trial.available_in: БГ
Overview
Feasibility Study of the Vessel Restoration System (VRS) for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery (SFA) and/or Popliteal Artery (PA) after Sub-optimal percutaneous transluminal angioplasty (PTA) or Atherectomy: REACTIVATE I
Who can participate
Inclusion Criteria: Subjects for this study must meet all of the following general eligibility criteria AND the answer must be "YES" to all general inclusion criteria: 1. Subject (or Legal Guardian) is willing and able to provide consent before any study-specific tests or procedures are performed and agree to attend all required follow-up visits. 2. Male or female subject of at least 18 years of age. 3. Chronic symptomatic lower limb ischemia defined as Rutherford classification 2, 3, or 4. 4. Has screen failed from the ACTIVATE II study due to the presence of Grade C or D dissection(s). Exclusion Criteria: 1. Life expectancy, documented in the Investigator's opinion, of less than 1 year. 2. Cerebrovascular accident (CVA) or transient ischemic attack (TIA) or cardiac event (e.g., PCI for STEMI/NSTEMI, unstable angina) within 6 months prior to the index procedure. 3. Chronic renal insufficiency with serum creatinine ≥ 2.5 mg/dL or eGFR \<45 ml/min within 30 days prior to the index procedure or treatment with peritoneal or hemodialysis. 4. Subject has a platelet count \< 100,000 cells/mm3 or \> 700,000 cells/mm3 within 30 days prior to the index procedure or has a history of bleeding diathesis. 5. Receiving oral or intravenous immunosuppressive therapy. 6. Subject has white blood cell (WBC) count \< 3.0 (3,000 cells/mm3) within 30 days prior to the index procedure. 7. History of major amputation in the target limb. 8. Any major intervention planned at the index procedure or within 30 days post-index procedure including treatment of contralateral limb. 9. Subject is pregnant, breastfeeding, or planning to become pregnant in the next 30 days. Subjects (male and female) of childbearing potential must agree to use effective birth control measures for 30 days after the index procedure.
Locations 1
Australia (1)
Flinders Medical Center
Adelaide , South Australia
Technical details
Status
Active (not recruiting)
Phase
Not applicable
Study type
INTERVENTIONAL
Sex
Male and female
Minimum age
18 Years
Healthy volunteers
No
Start date
15.11.2021
Completion date
15.11.2026
Registry ID
NCT05455021
Source
anzctr
trial.inquiry_btn

Information is automatically extracted from ClinicalTrials.gov. Consult your doctor before taking action.